Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

June 10, 2008 11:00 ET

Ambrilia to Present Its New HIV Integrase Inhibitors at the International HIV Drug Resistance Workshop

MONTREAL, QUEBEC--(Marketwire - June 10, 2008) - Ambrilia Biopharma (TSX:AMB) today announced that it will present in vitro and in vivo data on its new HIV integrase inhibitors, a result of a recent lead optimization effort, showing their improved activities against the HIV integrase enzyme and viruses. These data will be presented in a poster entitled "Small Molecule Inhibitors of HIV-1 Integrase" during a poster session on Wednesday, June 11, at the XVII International HIV Drug Resistance Workshop held this week, in Sitges, Spain (June 10-14).

A copy of the poster will be available on Wednesday, June 11, on the Company's website at


The International HIV Drug Resistance Workshop has gained a reputation over the last 16 years as being the premier meeting on HIV drug resistance. Leading laboratory and clinical scientists present their latest research at this Workshop, which often results in innovative approaches to antiretroviral therapy. The Workshop is renowned for the quality of the data presented and the depth of the scientific interaction and debate.


This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. There is a risk that expectations and forward looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward-looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's annual information form which contains a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery platform for cancer, a HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well antiviral small molecules (HIV integrase and entry inhibitors, HCV polymerase inhibitors) and peptides (HIV entry inhibitors, HCV entry inhibitors and FluA M2 proton channel inhibitors). Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Contact Information